title: Anti-macular degeneration agents.
abstract: Anti-VEGF therapy is a promising new avenue for the treatment of ocular neovascular diseases. Early preclinical data and recent clinical data support the efficacy and safety of several novel anti-VEGF for NVAMD. Whether these novel biologics are used on their own, in combination with previously available therapies, or with newly developing therapies, they represent a new avenue in treatment. These agents are highly selective in their targeted approaches, and when administered appropriately , offer treatment with minimal damage to retinal tissue. In the future, biotherapeutic agents will certainly play a powerful role in the treatment of human choroidal neovascular membrane formation.
authors.affiliation: Carolina Foundation for Macula Research and Education, Charleston, SC 29414, USA.
authors.forename: Michelle
authors.initials: M
authors.lastname: Rothen
authors.forename: Eric
authors.initials: E
authors.lastname: Jablon
authors.forename: Gerardo
authors.initials: G
authors.lastname: Monares
authors.forename: Monica Rodriguez
authors.initials: MR
authors.lastname: Fontal
authors.forename: D Virgil
authors.initials: DV
authors.lastname: Alfaro
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D017319:Photosensitizing Agents; D042461:Vascular Endothelial Growth Factor A